2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-4-amine | 905586-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-4-amine
• 英文别名: (2-chloro-pyridin-4-yl)-(5-cyclopropyl-1H-pyrazole-3-yl)-amine
• CAS: 905586-91-6
• 化学式: C₁₁H₁₁ClN₄
• 分子量: 234.688
• InChiKey: ZRPUBZWQPORQIB-UHFFFAOYSA-N

物化性质

• 沸点：
  464.2±45.0 °C(Predicted)
• 密度：
  1.465±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-4-amine 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 24.67h， 生成 2-(4-aminopiperidin-1-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-4-amine
  参考文献：
  名称：

  Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors

  摘要：

  The p21-activated kinases (PAKs) play important roles in cytoskeletal organization, cellular morphogenesis, and survival and have generated significant attention as potential therapeutic targets for cancer. Following a high-throughput screen, we identified an aminopyrazole scaffold-based series that was optimized to yield group I selective PAK inhibitors. A structure-based design effort aimed at targeting the ribose pocket for both potency and selectivity led to much-improved group I vs II selectivity. Early lead compounds contained a basic primary amine, which was found to be a major metabolic soft spot with in vivo clearance proceeding predominantly via N-acetylation. We succeeded in identifying replacements with improved metabolic stability, leading to compounds with lower in vivo rodent clearance and excellent group I PAK selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00572
• 作为产物：
  描述：

  2-氯-4-碘吡啶 、 tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以15%的产率得到2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-4-amine
  参考文献：
  名称：

  Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors

  摘要：

  The p21-activated kinases (PAKs) play important roles in cytoskeletal organization, cellular morphogenesis, and survival and have generated significant attention as potential therapeutic targets for cancer. Following a high-throughput screen, we identified an aminopyrazole scaffold-based series that was optimized to yield group I selective PAK inhibitors. A structure-based design effort aimed at targeting the ribose pocket for both potency and selectivity led to much-improved group I vs II selectivity. Early lead compounds contained a basic primary amine, which was found to be a major metabolic soft spot with in vivo clearance proceeding predominantly via N-acetylation. We succeeded in identifying replacements with improved metabolic stability, leading to compounds with lower in vivo rodent clearance and excellent group I PAK selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00572

文献信息

• Pyrazolylaminopyridine Derivatives Useful as Kinases Inhibitors
  申请人：Davies Audrey

  公开号：US20080139561A1

  公开（公告）日：2008-06-12

  This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有以下式（I）的新化合物，其制药组合物以及它们的使用方法。这些新化合物提供了一种治疗癌症的方法。
• Pyrazolylaminopyridine derivatives useful as kinase inhibitors
  申请人：Astrazeneca AB

  公开号：US08324252B2

  公开（公告）日：2012-12-04

  This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有式（I）的新化合物、其制药组合物以及它们的使用方法。这些新化合物提供了治疗癌症的方法。
• PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
  申请人：AstraZeneca AB

  公开号：US20130090358A1

  公开（公告）日：2013-04-11

  This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有公式（I）的新化合物，以及它们的药物组合物和使用方法。这些新化合物提供了治疗癌症的方法。
• WO2006/82392
  申请人：——

  公开号：——

  公开（公告）日：——
• US8324252B2
  申请人：——

  公开号：US8324252B2

  公开（公告）日：2012-12-04